Abstract
Drugs that block NMDA receptors, thereby inducing an NMDA receptor hypofunctional (NRHypo) state, can cause a disseminated pattern of irreversible neurodegeneration. Based on several lines of evidence, an N-methyl-d-aspartate receptor hypofunction (NRHypo) mechanism has been postulated to contribute to neurodegenerative changes in Alzheimer disease (AD). Because estrogen putatively exerts a neuroprotective effect in AD, we examined whether estrogen protects against NRHypo-induced neurodegeneration. We administered estradiol benzoate in three separate experiments to adult female rats: (1) 100 µg subcutaneously as a onetime dose, (2) 100 µg bid twice daily for 4.5 or 14 d, and 3) 300 µg twice daily for 4.5 d. Two hours after the last estradiol dose, MK-801 was administered (0.5 mg/kg subcutaneously) to produce a robust neurotoxic injury. Controls received MK-801, but no estradiol. Four hours after administration of MK-801, the severity of injury was evaluated histologically by quantitative methods previously described. Compared to controls, a single dose of estradiol produced no change in the severity of injury (p=0.24). Chronic treatment with estradiol was associated with a 25–35% reduction in the number of injured neurons (p<0.05 in all cases). We conclude that chronic but not acute estradiol treatment reduces the severity of NRHypo-induced neurodegeneration.
Similar content being viewed by others
References
Olney, J. W. (1978). In: Kainic acid as a tool in neurobiology. McGeer, E. G., Olney, J. W., and McGeer, P. L. (eds.). Raven: New York.
Watkins, J. C. (1978). In: Kainic acid as a tool in neurobiology. McGeer, E. G., Olney, J. W., and McGeer, P. L. (eds.). Raven: New York.
Olney, J. W. (1989). Biol. Psychiatry 26, 505–525.
Choi, D. W. (1992). J. Neurobiol. 23, 1261–1276.
Lipton, S. A. and Rosenberg, P. A. (1994). N. Engl. J. Med. 330(9), 613–622.
Olney, J. W., Labruyere, J., and Price, M. T. (1989). Science 244, 1360–1362.
Olney, J. W., Labruyere, J., Wang, G., Sesma, M. A., Wozniak, D. F., and Price, M. T. (1991). Science 254, 1515–1518.
Corso, T. D., Sesma, M. A., Tenkova, T. I., et al. (1997). Brain Res. 752, 1–14.
Farber, N. B., Kim, S. H., Dikranian, K., Jiang, X. P., and Heinkel, C. (2002). Mol. Psychiatry 7, 32–43.
Kim, S. H., Price, M. T., Olney, J. W., and Farber, N. B. (1999). Mol. Psychiatry 4, 344–352.
Olney, J. W., Wozniak, D. F., and Farber, N. B. (1997). Arch. Neurol. 54, 1234–1240.
Gonzales, R. A., Brown, L. M., Jones, T. W., Trent, R. D., Westbrook, S. L., and Leslie, S. W. (1991). Neurobiol. Aging 12, 219–225.
Wenk, G. L., Walker, L. C., Price, D. L., and Cork, L. C. (1991). Neurobiol. Aging 12, 93–98.
Magnusson, K. R. and Cotman, C. W. (1993). Neurobiol. Aging 14, 197–206.
Saransaari, P. and Oja, S. S. (1995). Mech. Aging Dev. 5, 171–181.
Ulas, J. and Cotman, C. W. (1997). Neuroscience 79, 973–982.
Wozniak, D. F., Dikranian, K., Ishimaru, M. J., et al. (1998). Neurobiol. Dis. 5, 305–322.
Olney, J. W., Wozniak, D. F., and Farber, N. B. (1998). Restorative Neurol. Neurosci. 13, 75–83.
Paganini-Hill, A. and Henderson, V. W. (1996). Arch. Intern. Med. 156, 2213–2217.
Hogervorst, E., Williams, J., Budge, M., Riedel, W., and Jolles, J. (2000). Neuroscience 101(3), 485–512.
Hurn, P. D. and Mhairi, M. I. (2000). J. Cereb. Blood Flow Metab. 20(4), 631–652.
Paech, K., Webb, P., Kuiper, J. M., et al. (1997). Science 277, 1508–1510.
Singer, C. A., Figueroa-Masot, X. A., Batchelor, R. H., and Dorsa, D. M. (1999). J. Neurosci. 19(7), 2455–2463.
Dubal, D. B., Shughrue, P. J., Wilson, M. E., Merchenthaler, I., and Wise, P. M. (1999). J. Neurosci. 19(15), 6385–6393.
Weaver, C. E., Park-Chung Mijeony, P., Gibbs, T. T., and Farb, D. H. (1997). Brain Res. 761, 338–341.
Moorandian, A. D. (1993). J. Steroid Biochem. Mol. Biol. 45, 509–511.
Toran-Allerand, C. D. (2000). Novartis Found. Symp. 230, 56–69.
Woolley, C. S., Weiland, N. G., McEwen, B. S., and Schwartzkroin, P. A. (1997). J. Neurosci. 17(5), 1848–1859.
Foy, M. R., Xu, J., Xie, X., Brinton, R. D., Thompson, R. F., and Berger, T. W. (1999). J. Neurophysiol. 81(2), 925–929.
Weiland, N. G. (1992). Endocrinology 131, 662–668.
Cyr, M., Othman, G., Thibault, C., Morissette, M., Landry, M., and Di Paolo, T. (2001). Brain Res. Rev. 37, 153–161.
Wong, M. and Moss, R. L. (1992). J. Neurosci. 12, 3217–3225.
Weiland, N. G. (1992). Endocrinology 131, 2697–2702.
Parducz, A., Perez, J., and Garcia-Segura, L. M. (1993). Neuroscience 53(2), 395–401.
Luine, V. N., Grattan, D. R., and Selmanoff, M. (1997). Brain Res. 747(1), 165–168.
Murphy, D. D., Cole, N. B., and Segal, M. (1998). Proc. Natl. Acad. Sci. USA 95, 11412–11417.
Rudick, C. N. and Woolley, C. S. (2001). J. Neurosci. 21(17), 6532–6543.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dribben, W.H., Nemmers, B.M., Nardi, A.R. et al. Chronic but not acute estradiol treatment protects against the neurodegenerative effects of N-methyl-d-aspartate receptor antagonists. Endocr 21, 53–58 (2003). https://doi.org/10.1385/ENDO:21:1:53
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:21:1:53